Claims for Patent: 8,343,929

Summary for Patent: 8,343,929

Title:	Treating neoplasms with neurotoxin
Abstract:	The present invention provides a method of treating a neoplasm using a neurotoxin, preferably botulinum toxin. Neurotoxin administered around a neoplasm acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze neoplastic cells through efferent channels leaving the neoplasm to distant sites. The present invention also provides a method of administering botulinum toxin at sites distant from the neoplasm, thereby enhancing cellular and humoral immunologic functions, which further contribute to neoplastic cell death. Following administration of botulinum toxin around or distant to a neoplasm as described herein, local, regional, and distant spread of neoplastic cells is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other diseases that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV.
Inventor(s):	Shaari; Christopher (Demarest, NJ)
Assignee:	Toxcure, Inc. (Demarest, NJ)
Application Number:	12/592,540
Patent Claims:	1. A method of weakening or paralyzing the muscle fibers surrounding a neoplasm in a patient, comprising applying to the non-cancerous area around said neoplasm a therapeutically effective amount of botulinum toxin in combination with an anti-cancer drug or anti-cancer therapy, such that the therapeutically effective amount of the botulinum toxin reduces the spread of cells from the neoplasm, thereby inhibiting the growth or metastases of the neoplasm. 2. The method of claim 1, wherein the botulinum toxin is administered before the anti-cancer drug or anti-cancer therapy is administered. 3. The method of claim 1, wherein the botulinum toxinneurotoxin is administered together with the anti-cancer drug or anti-cancer therapy. 4. The method of claim 2 or claim 3, wherein the anti-cancer drug is selected from the group consisting of: an alkylating agent, an antimetabolite, an anthracycline, mitoxantrone, topoisomerase, a mitotic inhibitor, a steroid, a differentiation agent, a hormone, and an immunotherapy agent. 5. The method of claim 4, wherein the mitotic inhibitor is selected from the group consisting of a taxane, an epothilone, and a vinca alkaloid. 6. The method of claim 5, wherein the taxane is paclitaxel or docetaxel. 7. The method of claim 6, wherein the taxane is paclitaxel. 8. The method of claim 1, wherein the botulinum toxin denervates muscle tissue surrounding the neoplasm. 9. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A or botulinum toxin type B.

Details for Patent 8,343,929

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2024-09-23